Download PDF
CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2021; 30(04): e277-e285
DOI: 10.1055/s-0041-1740291
Artículo Original | Original Article

Costoefectividad del régimen combinado de mirabegron/solifenacina en el tratamiento del síndrome de vejiga hiperactiva en Colombia

Cost-effectiveness of the Combined Regimen of Mirabegron/Solifenacin in the Treatment of Overactive Bladder Syndrome in Colombia
Pieralessandro Lasalvia 
1   Departamento de Estudios Económicos, Neuroeconomix, Bogotá, Colombia
2   Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia
,
Yaneth Gil-Rojas 
1   Departamento de Estudios Económicos, Neuroeconomix, Bogotá, Colombia
,
Fabián Hernández 
1   Departamento de Estudios Económicos, Neuroeconomix, Bogotá, Colombia
,
Camilo Castañeda-Cardona
1   Departamento de Estudios Económicos, Neuroeconomix, Bogotá, Colombia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Resumen

Objetivo Evaluar la costoefectividad incremental del régimen combinado de mirabegron/solifenacina en comparación con el uso temprano de toxina botulínica, desde la perspectiva del sistema de salud colombiano, para el tratamiento de adultos con vejiga hiperactiva.

Métodos Se empleó un modelo de Markov en que se comparan dos secuencias de tratamiento, una con y otra sin mirabegron/solifenacina, para evaluar la costoefectividad en un horizonte temporal de cinco años. Debido a la perspectiva de análisis, sólo se tuvieron en cuenta los costos médicos directos. La eficacia del tratamiento evaluado y su comparador fue medida en términos de la reducción de episodios diarios de incontinencia y de la frecuencia de micciones. Los costos fueron expresados en pesos colombianos de 2019, y se aplicó una tasa de descuento de 5% tanto para desenlaces como para costos.

Resultados Para el caso base, el costo del tratamiento en la secuencia que incluye mirabegron/solifenacina fue mayor, pero generó un mayor número de años de vida ajustados por calidad, y así e obtuvo una razón de costoefectividad incremental de $13.637,184 si se considera el desenlace de reducción de episodios diarios de incontinencia de 50%, y de $29.313,848 si se considera el del 100%.

Conclusiones De acuerdo con los resultados de esta evaluación, para un horizonte de análisis de cinco años, la secuencia de tratamiento con mirabegron/solifenacina es una alternativa costoefectiva, si se considera un umbral de disposición a pagar de tres veces el producto interno bruto (PIB) per cápita.

Abstract

Aim To evaluate the incremental cost-effectiveness of the combined regimen of mirabegron/solifenacin compared with the early use of botulinum toxin, from the perspective of the Colombian health system, for the treatment of adults with overactive bladder.

Methods A Markov model comparing two treatment sequences, one with and one without mirabegron/solifenacin, was used to assess cost-effectiveness over a five-year period. Due to the perspective of the analysis, only direct medical costs were considered. The efficacy of the evaluated treatment and its comparator was measured in terms of the reduction in the daily incontinence episodes and the frequency of micturition. The costs were expressed in Colombian pesos of 2019, and a discount rate of 5% was applied for both outcomes and costs.

Results For the base case, the cost of the treatment in the sequence that includes mirabegron/solifenacin was higher, but it generated a greater number of quality-adjusted years of life, thus obtaining an incremental cost-effectiveness ratio of $13,637,184 when considering the outcome of 50% of reduction in the daily incontinence episodes, and $29,313,848 when considering 100%.

Conclusions According to the results of the present assessment, for a five-year period of analysi, the mirabegron/solifenacin treatment sequence is a cost-effective alternative when considering a threshold of willingness to pay three times the per capita gross domestic product (GDP).

Palabras Clave

costoefectividad - mirabegron - solifenacina - terapia combinada - onabotulinumtoxina A - vejiga urinaria hiperactiva

Keywords

cost-effectiveness - mirabegron - solifenacin - combined therapy - onabotulinum toxin A - overactive bladder

Supplementary Material



Publication History

Received: 12 January 2021

Accepted: 04 August 2021

Article published online:
22 December 2021

© 2021. Sociedad Colombiana de Urología. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referencias

  • 1 White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin North Am 2016; 43 (01) 59-68
    CrossrefPubMedSearch in Google Scholar
  • 2 Marcelissen T, Cornu JN, Antunes-Lopes T. et al. Management of idiopathic overactive bladder syndrome: What is the optimal strategy after failure of conservative treatment?. Eur Urol Focus 2018; 4 (05) 760-767
    CrossrefPubMedSearch in Google Scholar
  • 3 Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: Evaluation and management. Curr Urol 2018; 11 (03) 117-125
    CrossrefPubMedSearch in Google Scholar
  • 4 Truzzi JC, Gomes CM, Bezerra CA. et al. Overactive bladder - 18 years - Part I. Int Braz J Urol 2016; 42 (02) 188-198
    CrossrefPubMedSearch in Google Scholar
  • 5 Plata M, Bravo-Balado A, Robledo D. et al. Prevalence of lower urinary tract symptoms and overactive bladder in men and women over 18 years old: The Colombian overactive bladder and lower urinary tract symptoms (COBaLT) study. Neurourol Urodyn 2019; 38 (01) 200-207
    CrossrefPubMedSearch in Google Scholar
  • 6 Invima. Acta N° 1 de 2020. Comisión revisora. Sala especializada de moléculas nuevas, nuevas indicaciones y medicamentos biológicos. https://www.invima.gov.co/documents/20143/1675737/Acta-No-01-de-2020-SEMNNIMB.pdf Published 2020. Accessed June 1, 2020.
    PubMed
  • 7 U.S. Food and Drug Administration (FDA). Summary products characteristicas: Mirabegron (Myrbetriq). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s011lbl.pdf Published 2012. Accessed June 1, 2020.
    PubMed
  • 8 Abrams P, Kelleher C, Staskin D. et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 2017; 35 (05) 827-838
    CrossrefPubMedSearch in Google Scholar
  • 9 Herschorn S, Chapple CR, Abrams P. et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 2017; 120 (04) 562-575
    CrossrefPubMedSearch in Google Scholar
  • 10 Drake MJ, Chapple C, Esen AA. et al; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol 2016; 70 (01) 136-145
    CrossrefPubMedSearch in Google Scholar
  • 11 Peng L, Zeng X, Shen H, Luo D-Y. Efficacy and safety of combinations of mirabegron and solifenacin in patients with overactive bladder: a systematic review and meta-analysis. Int J Clin Exp Med 2019; 12 (02) 1355-1365
    PubMedSearch in Google Scholar
  • 12 Instituto Nacional de Vigilancia de Medicamentos y Alimentos – Invima. Consulta de Registros Sanitarios. http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp Published 2019. Accessed May 27, 2018.
    PubMed
  • 13 Aballéa S, Maman K, Thokagevistk K. et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig 2015; 35 (02) 83-93
    CrossrefPubMedSearch in Google Scholar
  • 14 Bertapelle MP, Vottero M, Popolo GD. et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol 2015; 33 (08) 1109-1117
    CrossrefPubMedSearch in Google Scholar
  • 15 Castaño J, Lopera A, Orozco J, Valencia J. Cost utility analysis of sacral neuromodulation versus botox a in the treatment of overactive bladder in Colombia. Value Health 2014; 17 (03) A294
    CrossrefPubMedSearch in Google Scholar
  • 16 Hakimi Z, Kelleher C, Aballéa S. et al. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. J Mark Access Health Policy 2018; 6 (01) 1438721
    CrossrefPubMedSearch in Google Scholar
  • 17 Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en Salud. Bogotá D.C.: IETS; 2014
    Search in Google Scholar
  • 18 Drake MJ, Nitti VW, Ginsberg DA. et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 2017; 120 (05) 611-622
    CrossrefPubMedSearch in Google Scholar
  • 19 Kelleher C, Hakimi Z, Zur R. et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: A systematic review and network meta-analysis. Eur Urol 2018; 74 (03) 324-333
    CrossrefPubMedSearch in Google Scholar
  • 20 Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol 2018; 10 (12) 411-419
    CrossrefPubMedSearch in Google Scholar
  • 21 Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 2018; 8 (11) e021889
    CrossrefPubMedSearch in Google Scholar
  • 22 Nitti VW, Ginsberg D, Sievert K-D. et al; 191622-096 Investigators. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: Final results of a 3.5-year study. J Urol 2016; 196 (03) 791-800
    CrossrefPubMedSearch in Google Scholar
  • 23 Instituto de Seguros Sociales. Acuerdo 256 de 2001. Manual de tarifas de la Entidad Promotora de Salud EPS-ISS. https://lexsaludcolombia.files.wordpress.com/2010/10/tarifas-iss-2001.pdf. Published 2001. Accessed June 4, 2020.
    PubMed
  • 24 Detalle licitación SECOP II: Sistema de Salud de la Policía Nacional. https://construyored.com/licitaciones/colombia/258726580 Published 2019. Accessed November 26, 2019.
    PubMed
  • 25 Licitación pública: Subred integrada de Servicios de Salud Sur E.S.E. https://construyored.com/licitaciones/colombia/258726580 Published 2017. Accessed November 26, 2019.
    PubMed
  • 26 Kato D, Tabuchi H, Uno S. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Low Urin Tract Symptoms 2019; 11 (02) O152-O161
    CrossrefPubMedSearch in Google Scholar
  • 27 Ministerio de Salud y Protección Social (MSPS). Sismed - Sistema de información de precios de medicamentos. Reporte 2020. http://www.sispro.gov.co/recursosapp/app/Pages/Precios de Medicamentos - Circular 2 de 2012 Excel.aspx. Published 2021. Accessed April 10, 2021.
    PubMed